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Abstract
Autoimmune diseases occurs when the immune system recognize self antigens in the body as
foreign invaders leads to dysfunction of tissue. RA is an autoimmune disease, caused by improper
recognition of self-peptides, particularly human cartilage glycoprotein and type II collagen, by
specific human leukocyte antigen (HLA) receptors. Normally T-cell specific for these peptides are
destroyed in the thymus before they are released, preventing autoimmunity. However, certain posttranslational modifications, especially citrullination, can lead to “self-peptide” recognition by nonself T cells: in the case of RA, one HLA protein (DRB*0401), out of about 1700 possible ones, is
responsible for 65% of RA cases. If this protein could be blocked, drugs could be developed that
interrupt the disease at its root cause without affecting the rest of the immune system; this is the
focus of research in the Trant Lab. This thesis will briefly overview the approach, including the
drug design, and will focus on the molecular biology work accomplished to date. The main finding
of our thesis are as follows. Human leukocyte antigen is a protein needed to advance the research
and drug development in autoimmune diseases and cancers. In these early stages of this project,
we showed that choice of HEK293 cell as a host to express HLA protein and IMAC
chromatography as a purification system gives us a reasonable amount of α/β heterodimer
glycosylated membrane HLA protein.
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Introduction:
I.

Autoimmunity

i.

Autoimmune diseases

In recent decades, the prevalence and severity of autoimmune diseases (AD) such as type I
diabetes, multiple sclerosis, rheumatoid arthritis, autoimmune encephalomyelitis, and celiac
disease has increased dramatically in the western world: 7% of the population of the United States,
and 1.2% in the world as a whole, and the prevalence is still rising, possibly due to increases in
accurate diagnosis 1,2. Autoimmune diseases occurs when the immune system recognize self
antigens in the body as foreign invaders leads to dysfunction of tissue. Some autoimmune diseases
may be initiated by an infectious agent or a specific environmental exposure 3. Autoimmune
diseases can impact a specific organ, or they can be systemic which leads to a wide range of
symptoms and organ injuries depending on the site of autoimmune attack. The main factor causing
the autoimmune disease is still unknown, however genetic factors certainly play a key role at least
in susceptibility 4.

Most autoimmune diseases do not have cure, and the available treatments have detrimental effects
on the quality of life for these patients. Many of these patients around the world losing their job
because of less productivity at work, loss of organ function and enduring debilitating symptoms.
Generally, females are affected more frequently than men and autoimmune diseases remain among
the leading causes of death for young and middle-aged women which imposes a heavy burden on
the patient’s family and on society 3,5. Today, autoimmune diseases are treated with
immunosuppressive agents that non-specifically reduce the severity of symptoms by weakening
the whole immune system which make the patients more susceptible to infection and cancer. As a
result, a promising therapeutic could be the one which can cure the autoimmune disease
specifically by targeting the origin of the disease without affecting the rest of the immune system.
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ii.

Tolerance and autoimmunity

The key role of the immune system is to recognize self from non-self antigens 3. The immune
system is tolerant of self-antigens; as a result the immune system should not attack the body’s own
cells, tissues, and organs6. The presence of antigens in immune cell-inaccessible anatomic sites
like the central nervous system and eye tissues prevents lymphocytes from interacting with them.
The main consequence of antigen ignorance by lymphocytes is the absence of any type of immune
response 7. Immune tolerance refers to unresponsiveness of the immune system toward certain
substances or tissues that are normally capable of stimulating an immune response. Self-tolerance
is essential for normal immune balance, and failure or breakdown of that tolerance results in
autoimmunity and autoimmune diseases8.
Immune tolerance comprises both central and peripheral tolerance 9. The major mechanism of the
central immune tolerance is the negative selection in the thymus. The complementary mechanism
which abandons the expansion and reactivity of mature self-reactive cells is peripheral tolerance.

Central tolerance, known as negative selection occurring in the thymus for T cells and bone
marrow for B cells, is the primary way that the immune system discriminates self from non-self.
Central tolerance refers to the elimination of autoreactive lymphocyte clones before they become
fully immunocompetent, of which the main mechanism is negative selection 10. This procedure
occurs during lymphocyte development in the thymus and bone marrow for T and B lymphocytes,
respectively. After T and B lymphocytes enter the peripheral tissues and lymph nodes, peripheral
tolerance will occur to inhibit immune responses against the body's own tissues, which occurs
primarily in the secondary lymphoid organs, such as the spleen and lymph nodes. Peripheral
tolerance, which occurs in tissues and lymph nodes after lymphocyte maturation, controls selfreactive immune cells and prevents overreactive immune responses to various environmental
factors. Mechanisms of peripheral tolerance include anergy (functional unresponsiveness),
deletion (apoptotic cell death) and suppression by regulatory T cells 11’10. Loss of tolerance results
in autoimmune disorders, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA),
type 1 diabetes (T1D) and primary biliary cirrhosis (PBC) 12. Autoimmune diseases may develop
when self-reactive lymphocytes escape from tolerance control mechanisms; thereby the loss of
tolerance leads to autoimmune diseases13.
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iii.

The mechanisms of T cell selection in the thymus in autoimmunity

T lymphocytes are one of the important components of adaptive immune system response,
containing T-cell receptor on their cell surface. These T cells can recognize antigens and are
activated when they bind to preformed complexes between peptide antigens and the major
histocompatibility complex (MHC) protein on the surface of antigen presenting cells. As a result
of activation, T-cells initiate a series of downstream signalling pathways that lead to cytokine
secretion and T cell proliferation14. T cells arise in the bone marrow; however, they migrate to the
thymus gland to mature. In the cortex of the thymus, T cell precursors known as thymocytes
proliferate and differentiate into CD4+ and CD8+ cell types. When CD4+ and CD8+ T cells
recognize the peptide-MHC on cortical thymic epithelial cells, based on the affinity with different
classes of MHC, they differentiate into CD4- and CD8- single positive T cells. This process is
called positive selection. So, positive selection ensures that the developing thymocytes have
assembled proper T cell receptors and are capable of recognizing peptide-MHC complexes.

Negative selection happens when developing thymocyte recognize self-antigen-MHC complexes
with very high affinity. High affinity of binding means that this particular T cell will most likely
react against this self-antigen-MHC complex and should be eliminated. Low affinity interactions
are not eliminated as they would be insufficient to active Tcells(Figure 1). In the medulla, CCR7
ligands CCL19 and CCL21 are expressed by medullary thymic epithelial cells (mTECs), and they
interact with the chemokine receptor CCR7 expressed by CD4 or CD8 T cells These interactions
lead to the deletion of autoreactive T cells. This activity is essential to protect the body from
circulating T-cells that would initiate an immune response against the self. This is extremely
dangerous and leads to autoimmune disease. However, occasionally self-reactive T-cells escape
these control mechanisms and can lead to diseases like rheumatoid arthritis should they react to a
series of synovium or collagen-related peptide sequences.

3

Figure 1 The mechanism of positive and negative selection in Thymus
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II.

Rheumatoid Arthritis

A healthy joint consists of two adjacent bony ends completely covered in cartilage to prevent
friction. The articular cavity is the space between these two ends containing synovial fluid and a
thin layer of cells forming by two types of synoviocytes: type A or macrophage-like synovial cells
and type B or fibroblast like synoviocytes (FLSs). Together these cells make the synovial
membrane. The synovial membrane is responsible for producing synovial fluid, the lubricant
between the cartilage (Figure 2).
Rheumatoid arthritis, or RA, is an inflammatory autoimmune disease. that causes chronic synovial
inflammation which leads to joint destruction and disability 15. The confluence of genetic
susceptibility and environmental factors recruit multiple components and steps in both the innate
immunity, a nonspecific defense mechanism of the body and adaptive immune system, a specific
defence process which are involved in the initiation of autoimmune diseases. In RA, synovial fluid
is invaded by macrophages, dendric cells, plasma cells and T cells which are components of innate
and adaptive immune systems involved in pathobiology of RA.4

Over the years, the prevalence of rheumatoid arthritis has increased globally. According to the
Arthritis Society of Canada, 1.2% of Canadians has RA (with 20% have some form of arthritis).
RA leads to swelling in the small joints of the hands and feet in which it can damage the joint and
affect other organs such as eyes, skin, lungs, and the heart if the inflammation continues untreated.
The symptoms of RA vary in different patients. Many patients, experience non-specific symptoms
such as fatigue, soreness in joints and muscles, weight loss. On the other hand, some RA patients
experience severe symptoms dramatic morbidity and premature mortality 16. Unfortunately, there
is no cure for RA and current therapies can only avoid pain and joint damage to help the patients
live longer. As a result, it is important to find a cure for RA as most of the patients suffer physical
and social consequences. Many patients with RA are at the higher risk of chronic diseases such as
heart disease, diabetes, blood pressure and high cholesterol.
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Figure 2. A cartoon comparing healthy and Arthritic joints.
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ii.

Major Histocompatibility Complex

The major histocompatibility complex (MHC) is located on chromosome 6 at locus p21.3 in humans (Figure
3A), and on chromosome 17 in mice18. MHCs are a class of molecules that bind peptides derived from
cellular proteins and display them for surveillance by the immune system 19. MHC molecules are the key
elements in the development of humoral and cell-mediated immune responses20. Each person has a limited
repertoire of MHC proteins, also call the human leukocyte antigen(HLA) inherited in a Mendelian fashion
for each class. Fortunately, each HLA protein can host various peptides, and since everyone has one or two
alleles at each of the classical loci (HLA-A, B, and C for class I, and HLA-DP, DQ, and DR for class II), a
large number of antigens can be effectively eliminated 21. However, compared to the number of possible
pathogen antigens, and, as we shall see, the number of possible T-cell receptors that can recognize antigenHLA complexes, the number of HLAs remains very low. Important in terms of terminology, in humans,
the MHC proteins are called the Human Leukocyte Antigen receptor proteins (HLA), and HLA and MHC
will be used throughout the rest of this thesis. In general HLA will be used when discussing specific proteins
or clinical ramifications, while the more species-non-specific term MHC will be used for discussions of the
protein class in isolation.

The HLA gene products are divided into two main classes: class Ⅰ and class Ⅱ. Both share a similar
three-dimensional structure in which the antigen binding groove is composed of two domains
originating from a single heavy α-chain in HLA class Ⅰ and from two chains (α-chain and β-chain)
in HLA class Ⅱ.

HLA class I genes consist of three classic loci and three non-classic ones that are less polymorphic.
The classic loci are HLA-A, -B, and -C, whereas the non-classics are HLA-E, -F and -G19,22. HLA
class Ⅰ molecules consist of one membrane-spanning α chain (heavy chain) and one β2microglobulin (light chain) (Figure 3B). They are expressed on almost all nucleated cells, and they
present 8-10 amino acid peptides to cytotoxic T cells 23. HLA class Ⅱ genes, on the other hand, are
expressed only on antigen-presenting cells, such as macrophages, dendritic cells, and B cells
(Figure 3C). They present 14-18 amino acid peptides to helper T cells 24.
The source of antigens is cytosolic proteins for HLA class Ⅰ and endosomal and lysosomal proteins
for HLA class Ⅱ 25. In HLA class Ⅰ, the antigens are degraded by cytosolic and nuclear
proteasomes. Transporters associated with antigen presentation (TAP) translocate the antigen into
the endoplasmic reticulum (ER) to access HLA class Ⅰ. TAP is a member of the ATP-binding
cassette family of transport proteins, and each TAP has two subunits (TAP1 and TAP2) 26. Once
the antigens are in the ER lumen, ER aminopeptidases ERAAP/ERAP1 and ERAP2 trim them to
HLA I’s preferred length of 8-10 residues. TAP also associates with the HLA-I heavy chain, β2microglobulin, tapasin, calreticulin, and ERp57. This collection of proteins is called the peptideloading complex, and it facilitates the binding of an antigen to an HLA I molecule. Once the two
components join, the loaded HLA I molecule travels to the cell surface. Following the assembly
of α and β heterodimers, HLA class Ⅰ needs the peptide as a third part for stability-without the
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peptide it dissociates, misfolds, and is marked for degradation. After accommodating the peptide
in the peptide binding groove, the assembled peptide-HLA complexes leave the ER to present the
peptide to CD8+ T cells 27,28(Figure 4).

HLA class II consists of three subclasses of genes: DR, DQ, and DP (Figure 3A). While the DNA sequences
for α-chain are almost conserved in each class, those for β-chain present polymorphism, resulting in the
diversity and specificity of peptide binding 29. In the DR subclass of HLA (HLA-DR), the α-chain is
exclusively coded by the DRA*01:01 allele whereas the number of allelic variants of the β-chain (DRB)
exceeds 1700 30. Individuals can also have multiple copies of each locus, although the number of copies
varies between individuals.
HLA class II molecules are assembled in the ER with a peptide called the invariant chain (Ii), which acts
as a pseudo antigen by filling the HLA class II peptide-binding groove during this assembly and keeping
them intact before they associate with antigens. These antigens for the HLA class II are endocytosed from
the external environment, degraded in the endosomal pathway, and then transported in the form of vesicles
or tubules to the plasma membrane 31 (Figure 5).
This series of molecular interactions is essential for a properly working immune system. It is when the
antigen, instead of being derived from a foreign pathogen, is self, and when a T-cell with a receptor that
recognizes self peptide-MHC complexes manages to escape the thymus, that autoimmune disease is
initiated.
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Figure 3 (A) MHC genes in humans, (B), MHC class II molecule, (C) Antigen
Presenting Cells
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Figure 4 MHC class I assembly 32
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Figure 5 MHC class II pathway (picture from Nature Reviews Immunol ogy)
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iv.

Pathogenesis of Rheumatoid Arthritis

An interaction between genetic and environmental elements contributes to the pathogenesis of RA.
Environmental risk factors such as smoking, infectious agents, and hormones have a role in
causing RA; however, genetic risk factors are responsible for about 60% of the risk in developing
RA.33 This autoimmune disease is caused by improper recognition of self-peptides, particularly
human cartilage glycoprotein and type II collagen, by specific human leukocyte antigen (HLA)
receptors34. Major histocompatibility antigens/human leukocyte antigens (specifically those at the
HLA-DR loci) and some non-HLA genes have been linked with the pathogenesis of RA. It is well
established that HLA-DRB1*01, HLA-DRB1*04, HLA-DRB1*1001, HLA-DRB1*13 and HLADRB1*15 containing shared epitope (SE), a five amino acid motif (QKRAA) in the third allelic
hypervariable region of HLA-DRβ chain, are associated with the pathogenesis of RA.

Autoimmunity and autoimmune diseases are considered to be driven mainly by adaptive immune
responses, namely by auto-reactive B and T cell over-activity35. T lymphocytes contribute in
multiple steps to the immunopathogenesis of RA 36. The diversity of the disease process and
lymphoid microstructure illustrates that multiple T cell activation pathways are involved. CD4 T
cells are the main key lymphocyte in the synovial infiltrate and play a crucial role in pathologic
immune response. Antigen-presenting cells including macrophages, dendritic, and active B cells
present autoantigens to CD4+ T cells in the context of MHC class Ⅱ. These cells are known to be
the most potent activators and modulators of the adaptive immune system. They reside in
peripheral tissue, and they capture and transfer antigens from the outside world to the cells of the
adaptive immune system 37,38. Therefore, CD4+ T cells secrete IL-2 and IFN-γ and infiltrate the
synovial membrane, and results in increasing of the lining layer of the joints. T cells in rheumatoid
arthritis infiltrate the synovial membrane to transform the macrophages and synovial fibroblasts
into tissue destructive effector cells39. IL-5 is the main cytokine growth factor for synovial T cells;
however, rheumatoid arthritis is considered a T helper 1 cell-mediated disorder, and some studies
showed the presence of T helper 17 in synovial membrane. There are different cytokines
contributing to expansion and differentiation of TH1 and TH17 cells such as IL-1β, IL-6, IL-17,
IL-12, IL-15, IL-18, IL-23P19 and TGFβ.40 This list of exacerbating cytokines provides many
possible targets for therapy; but simultaneously, these are high risk targets as they are all also
involved in the normal immune response to pathogenic infection: any modulation of their activity
must involve very careful balance as dysregulating them can lead to significant
immunocompromisation, infection, or increased tumorigenesis.

Moreover, B cells play a key role in pathogenesis of RA by producing antibodies, autoantibodies,
and cytokines. The most common autoantibodies in RA patients are RF and anti-CCP (cyclic
citrullinated peptides). Rheumatoid factors (RF) are a family of autoantibodies against Fc portion
of IgG. B cells in the lymphoid follicles and germinal center produce RF in RA patients. RF have
been detected in 60-80% of RA patients. Anti-citrullinated protein antibodies (ACPAs) are the
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other main diagnosis factors with high sensitivity (97%) in RA patients. ACPA is a result of an
antibody response to a variety of citrullinated proteins such as fibrin, vimentin, Epstein-barr
Nuclear Antigen 1 (EBNNA-1), type Ⅱ collagen in the body. HLA-DR1 and HLA-DR4 are found
as the strongest genetic risk factor associated with ACPA- positive RA. As a result, RF and ACPA
are the most significant autoantibodies which results in different pathophysiological information41,
17
. The continuous stimulation of dendritic cells by autoantigens ( fibrin, vimentin, Epstein-barr
Nuclear Antigen 1 (EBNNA-1), type Ⅱ collagen increases B cell activity drives auto-reactive B
cells to increase the production of autoantibodies and pro-inflammatory cytokines. Macrophages,
besides presenting autoantigens to the immune system, are involved in osteoclast genesis which
are multinucleated cells in charge of resorption of bone. 42
On the other hand, pro-inflammatory cytokines such as IL-6 and TNF-α, IFN-γ, and IL-1, have a
significant effect on the pathogenesis of RA by osteoclast activation, increasing monocyte
activation and production of synovial fibroblast cytokines, respectively. Cartilage degradation in
RA patients happens when these pro-inflammatory cytokines activate synoviocytes, , which leads
to MMPs (Matrix metalloproteinases) secretion into SF (Synovial fluids). 43 All in all, we can
conclude that CD4 T cells are the main mediators in pathobiology of Rheumatoid Arthritis and
targeting this mechanism will be essential for the development of promising therapeutic for RA.
The molecular mechanisms and feedback loops are complicated and disorienting: however, it is
important to note that once the initial response is initiated, triggered by the presence of the antigen,
the downstream cytokine responses discussed here are common to almost all inflammatory
responses to pathogen or antigen presence. Again, although this apparently provides a myriad of
drug targets, all of these molecular targets are common to the rest of the immune system and are
required for proper function. Targeting these systems needs to be done very cautiously; it can be
seen as akin to a police force, trying to catch a thief to keep a city running well, arresting the entire
population. It will certainly capture the thief, but it will also prevent the city from running well. A
more targeted approach is required (Figure 6).
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Figure 6 Components of adaptive and innate immune system involved in the
pathogenesis of RA.
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iii.

Ectopic Lymphoid Structures in Rheumatoid arthritis

Ectopic (or tertiary) lymphoid structures (ELS) are organized aggregates of lymphocytes
resembling secondary lymphoid organs and developing in the target organs of patients affected by
autoimmune diseases, such as salivary glands in SS 44, synovial tissue in RA 45, kidneys in SLE 46,
meninges in MS 47, and thyroids in Hashimoto’s thyroiditis. In autoimmune diseases, ELS play a
role in chronic inflammation and maintaining the disease process leading to a severe disease
course48.

Innate immunity cells and FLS contribute to the formation of ELS by infiltrating lymphoid cells
into synovia and making secondary B-cell follicles with germinal cells and T cell compartments
containing dendritic cells. It is believed that these immunological components facilitate the antigen
presentation at the place of inflammation to trigger the immune system. ELS can destroy the tissue
specifically, cartilage and joints by exposing continuously with autoantigens at the site of
inflammation. In RA, the synovium, the soft tissue that lines the inner surface of joints, is the
place of heterogeneous infiltration of leukocyte, synovial lining hyperplasia, and
neovascularization resulting in the destruction of cartilage, bone erosion and joint disability.
The mediators involved in the process of ELS formation are lymphotoxin-β (LTβ), CXCL13,
CCL19, and CCL2149. These lymphoid chemokines play a key role in ELS development. The
lymphoid chemokines, CXCL13, CCL19 and CCL21 can be upregulated in rheumatoid synovium.
The high level of these chemokines is also associated with the upstream regulation of ELS
organization. Studies have shown that in rheumatoid synovium haematopoietic cells including
CD14+/CD68+ monocyte/macrophages and memory T cells are producing CXCL13. So, all the
cells in the innate and adaptive immune system help to recruit and organize the B cells.
Particularly, B-cell aggregates with the feature of ELS is associated with the expression of
CXCL13. As a result, CXCL13 and CCL21 are the main chemokines contributed in the maintain
and function of ELS.
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vi.

Treatment strategies in rheumatoid arthritis

As referenced above, current, and emerging therapeutics either treat the symptoms of the disease
or non-specifically weaken the immune response to reduce symptom severity by targeting some
of the cytokines involved in the immune response. Some nonsteroidal anti-inflammatory drugs
(NSAIDs) like aspirin, ibuprofen, or naproxen are used by some patients on a regular basis to
relieve the pain. This family of drugs blocks the cyclooxygenase (COX) enzymes. COX trigger
the production of prostaglandins, which are the mediators causing inflammation and pain. The
main potential side effect of NSAID overuse is inhibiting platelet aggregation leading to dramatic
gastrointestinal disorders such as bleeding, ulcers, and perforation. 50 The other group of drugs
which is common between patients with severe RA is glucocorticoids. These drugs bind to their
specific receptors and inhibit cellular signaling pathways 51. Although this family of drugs is
significantly effective in the treatment of RA, the adverse side effects are one of the main concerns
such as infection, gastrointestinal problems, ophthalmologic effects. 52. To reduce inflammation,
disease-modifying anti-rheumatic drugs (DMARDs) were developed. DMARDs are common in
the treatment of autoimmune diseases like RA. Methotrexate, an analog and antagonist of folic
acid, inhibits folate-dependent enzymes, it also inhibits purine and pyrimidine synthesis which are
necessary for DNA and RNA synthesis. Leflunomide is another drug from DMARDs family drug
abandon the synthesis of de novo pyrimidine ribonucleotides As a result they supress the
production of pro inflammatory cytokines 53. As mentioned in the pathogenesis of RA, proinflammatory cytokines such as IL-6 and TNF-α, IFN-γ, and IL-1 are abundant in these patients
in which TNF is considered a key proinflammatory cytokine in autoimmune diseases, as a result
discovery of anti-TNF biologics such as infliximab, etanercept, adalimumab, golimumab, and
certolizumab pegol has been a gold standard therapeutic drugs in the past decades for autoimmune
diseases 54 55.

In addition to anti-TNF biologics, other biological drugs suppressing proinflammatory cytokines
have been developed. Abatacept, a humanized fusion protein of extracellular domain of TLA-4
and Fc fraction if IgG1, selectively inhibits CD80-CD86 and activation of T cells. The other
biologic drug is Tocilizumab: a humanized anti-IL-6 receptor monoclonal antibody that blocks the
transmembrane signaling of IL-6. Other biological drugs targeting other pro-inflammatory
cytokines such as IL-1, IL-12, IL-23, IL-17, and CD20 have been approved as a complementary
treatment of anti-TNF therapy.

Although anti-TNF biologic drugs have been used in the treatment of AD progressively, the
adverse side effects of these drugs should be taken into consideration. Studies have shown that
anti-TNF biologics may, unsurprisingly, have major impacts on TNF expression in patients.
Moreover, patients with TNF-alpha 308G > A polymorphism do not respond to ani-TNF therapy56.
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TNF is one of the major arms of immune system to defend the body against pathogens by inducing
nitric oxide in macrophages, triggering IFN-γ to induce inducible nitric oxide synthase (iNOS). As
a result, using the anti-TNF biologics to block TNF expression, is certainly a great concern due to
reactivation of tuberculosis and pneumonia leading to new bacterial infection. Anti inflammatory
treatment promotes the risk of cancer, so patients with malignancy should be carefully studied
after anti-TNF biologics 57. Consequently, effort has been made to target the HLA-antigen
interaction, the one molecular event that is unique to RA and is not involved in any other immune
response. Preventing self-peptides from initiating an immune response would mean that we would
be able to prevent RA without affecting any other normal component of the immune system.

Family of Drugs

Drugs

Non-Steroidal Anti- Traditional nonInflammatory
selective NSAIDs
Drugs (NSAIDs)

Glucocorticoids,
(corticosteroids)

Conventional
Disease-Modifying
Anti-Rheumatic
Drugs (cDMARDs)

Target

Side effects

Inhibit
cyclooxygenase
(COX) enzymes

Gastrointestinal disorders,
renal toxicity,
cardiovascular system

Selective
cyclooxygenase-2
(COX-2) inhibitors

Inhibit
cyclooxygenase
(COX) enzymes

Dexamethasone and
betamethasone

Inhibit cellular
signaling pathway
such as AP-1 and
NF-κB

Gastrointestinal ulcers and
bleeding, infection,
immunosuppression, and
bone damage

Methotrexate

Inhibit the activity
of folatedependent
enzymes, and
synthesis of purine
and pyrimidine
which are required
for DNA and RNA
synthesis

Adverse effect on skin and
mucosa,
reversible and irreversible
renal disease, hypertension,
and heurism

Leflunomide
Inhibit the
synthesis of de
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novo pyrimidine
ribonucleotides
Biologics

Abatacept

Suppress T cells

Biologics

Rituximab

Suppress B cells

Anti-TNF
Biologics

Infliximab

Inactive binding
of TNF to its
soluble and
membrane
receptors

Etanercept

Inactivates soluble
form and
membrane form of
TNF and
lymphotoxin

Adalimumab

Block human TNF
binding to its
receptors

Golimumab

Neutralization of
soluble and transmembrane forms
of TNF

Certolizumab Pegol

TNF inhibitor

Not all patients respond
equally well to the
treatment, infections, such
as tuberculosis and
pneumonia, are common
adverse event of patients
treated with anti-TNF
biologics, malignancy, side
effects on the neurological
system
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III.

Definition of Altered Peptide Ligands

Peptides derived from antigens are the major element in causing the autoimmune diseases which
have been a potential target of treating autoimmune diseases. Two general approaches are possible.
The first, altered peptide ligands (APLs), are analogues derived from the original antigenic peptide
that aim at triggering different classes of T-cells to balance the pro-inflammatory response with an
anti-inflammatory response. The second are HLA-blockers (HLABs), which seek to stop the
immune response by quantitatively displacing antigenic peptides and also preventing any T-cell
receptor interaction with the MHC-HLAB complex. (Figure 7).

Specific recognition of an immunogenic peptide epitope by T cell receptor triggers the immune
system. A strategy for immune evasion would be helpful to prevent the T cell response. Altered
peptide ligands, analogues derived from the native peptides with single or few amino acid changes
can regulate the immune responses. APLs can antagonize and inhibit T cell activation and
discovery of APLs have been an immune therapeutic peptide to stop the immune response where
the T cell activation can play a key role in the immunopathology of autoimmune diseases. Many
APLs have been designed in peptide-based research by replacing the single amino acids in an
immunogenic peptide to check the outcome of T cell proliferation and cytokine production. 58 The
modification of Alanine to Leucine in the melanoma-associated Mart-1/Melan-A(26-35) epitope
EAAGIGILTV that cause enhances MHC-binding is a famous example of APLs59. Three different
APLs with a couple of substitutions of key residues have been designed for TCR and HLA-DR
recognition in rheumatoid arthritis patients. These APLs are produced based on native peptides
such as Collagen II (CII), human cartilage glycoprotein-39 (HCgp-39) and binding protein (BiP).
Results on peripheral blood mononuclear cells (PBMCs) of RA patients have been illustrated that
mutation in the main contact residues are able to abandon the immune responses; However, APLs
may result in unanticipated and unwanted side effects and have adverse events in the patients 60.
TCR polymorphism means that a peptide that initiates a strong anti-inflammatory Th2 response in
one individual can initiate a strong pro-inflammatory Th1 response in another (Figure 7). Some
studies have been showed the APLs generated from myelin sheath are able to change the responses
from Th1 the stimulator of cellular immune response by macrophage inhibition to Th2, the
subgroup of T cell stimulating humoral immune response and promoting cell proliferation and
antibody production and inhibit EAE. Moreover, several patients developed immediate
hypersensitivity and immune responses due to the cross reactivity with the native antigens and
high production of IFNγ and low IL-4 were reported in some cases60. The primary risk for these
systems is that they are highly personal: similar TCRs able to recognize the same MHC-APL
complex might be anti inflammatory in many patients, but proinflammatory in others, or highly
immunogenic in a third group. Although careful ex vivo testing of an individual’s response to
APLs might be able to mitigate the risk and identity those likely to benefit from those likely to
exhibit extreme adverse, and potentially fatal, responses, the approach still retains risk as reactive
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TCRs could be present in very low concentrations and not immediately respond to the testing of
the therapy. This inherent risk has been one of the reasons that no APL has ever been approved for
clinical use.
APLs have one major benefit though: as they are designed to balance the immune response, they
do not need to prevent antigen binding, they only need to balance it. This means that they do not
need to exhibit exceptional affinity for the binding groove in comparison to the natural antigens.
This does make their design a lot more flexible and easier.
Glatiramer acetate is an approved drug for the treatment of relapsing and remitting of Multiple
sclerosis. It consists of salts of synthetic polypeptides containing random chains of four naturally
amino acids. This drug competes with myelin basic protein for biding to MHC molecules (HLADRB1) and downregulate inflammation by secretion of anti-inflammatory cytokines. However, it
is generally received that this is only one of the mechanisms of action of this drug, and not likely
the one primarily responsible for the observed anti-autoimmune effects. But it does indicate that
peptide drugs which could be accommodated in the MHC binding groove with strong and high
affinity could be a promising peptide drug which cure the autoimmune diseases 61.

Figure 7 Schematic picture of the different outcomes of APLs and HLABs 61
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IV.

Human Leukocyte Antigen Blockers

Some new strategies such as Human Leukocyte Antigen Blockers (HLABs) are needed to block
the HLA with high and strong affinity aim to displace the antigenic peptides from the HLA
quantitively could cure autoimmune diseases.

HLABs are peptide drugs that possess several features: exceptional binding affinity (we estimate
>10,000-fold that of immunogenic antigens), no immunogenicity, high protease resistance, and
facile up-take by antigen-presenting cells. The HLABs can displace the disease-causing peptides
with higher affinity. As a result, they prevent T cells from recognizing the HLAB-HLA complex
to ensure that that they do not initiate the immune responses and halt the immune response in
autoimmune diseases without any impact on the rest of the immune system.

The natural antigen must be quantitatively displaced for an HLAB strategy to work. This requires
the drug to have exceptional affinity for the HLA; however, after a decade of effort, it is now clear
that the required increase in affinity is not attainable using natural residues. HLA binding pockets
are not specific for any given residue, the HLA must be able to bind a wide variety of peptide
ligands and so no pocket can be specific for any amino acid. The required relative improvements
in binding affinity are simply not available using natural amino acids. Exhaustive screens have
been conducted for celiac disease by the groups of Khosla, Sollid, and Konigs over the past couple
of decades demonstrating this is unfeasible. But this does not mean that the HLA binding groove’s
pockets do not have a defined 3-dimensional structure. It just means that no natural residue fits
very well. Consequently, we need to design new residues to fit these pockets. This is the core
innovation of the Trant lab’s research approach62. Our computational chemists have designed
peptides with non-conical amino acids which can bind with high affinity and accumulate in the
empty binding groove space of HLA-DR4, and that will be able to quantitatively displace any
antigen present in the groove due to their exceptional affinity.
However strong binding is insufficient: this would just lead to a new antigen-HLA complex that
would likely be recognizable by circulating T-cells and we are left with the same issue faced by
APLs. However, TCRs must recognize key points on both the antigen and the HLA to bind. Should
the TCR be physically prevented from binding, then it can’t recognize the receptor and we can
render it invisible to the immune system. This can be accomplished by cyclizing the peptide. Figure
8b shows a cyclic peptide resting in an HLA (DR1). The peptide surface is presented as a blue
wire mesh, the HLA as a ribbon structure and the TCR as a string structure. In 8c, the TCR surface
of the same view is now provided. It needs to occupy the precise space occupied by the “blocking
arc” of the peptide. Figure 8a provides a cartoon representation of this strategy. The group is
focusing on building new, and using established methods, to cyclize peptides and build them from
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unnatural amino acids to make these types of drugs. However, the drugs are useless without a
means to evaluate them.
The main goal of this thesis is to develop a reliable method to express and purify the HLA-DR4
protein, so that we can evaluate the binding affinity of the purified protein with the peptide drugs
designed in our lab to aid in the design of these novel therapeutics.
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A

B

C

Figure 8 A cartoon illustrating HLABs. (Made by John Trant, unpublished figure,
2015 Figure) B. a cyclic peptide resting in an HLA (DR1). C. the TCR surface (Made
by Taimoory and Trant, unpublished result, 2018).
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Hypothesis
We hypothesize that because Human Leukocyte Antigen is a human α/β glycosylated protein,
mammalian cell culture will be the best expression system and also the Human Leukocyte Antigen
Blockers (HLAB) will be able to competitively displace and prevent the binding of disease-causing
peptides in the HLA. We hypothesize that our HLABs will prove to be non-immunogenic in a DR4
mouse model, and that, when co-administered with the immunogenic peptide, will prevent the
emergence of RA compared to positive control models (where the peptide is administered). We
employed computational design to identify non-natural amino acids that fit the HLA binding
pockets unsatisfied by natural amino acids. After synthesis we will measure our HLABs’
experimental affinity for the HLA, and their efficacy in vitro, in a novel human ex vivo model,
and in vivo in mice.

Objectives
Long-Term Objectives:
To generate new HLAB peptide therapies for RA, and to develop chemical tools that will allow
immunologists, for the first time, inhibit an HLA-TCR interaction.
Medium-Term Objectives for the Trantteam:
•
•
•

Design, synthesize and determine the in vitro binding affinity of HLABs targeting RA associated
HLA-DR4.
3-D print synovium (the tissue inflamed in rheumatoid arthritis) and use it as an ex vivo model of
RA
Determine the efficacy of HLABs in vitro and in vivo.

Short term:
To generate a proper method to express and purify Human leukocyte Antigens for structural and
biophysical studies, functional assays, drug development and for therapeutic applications assays.
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Materials & Methods:
Plasmids
The pHLsec DRA DNA & pHLsec DRB1*0401 DNA plasmids were a gift from Stephen W.
Scally, Monash University, Australia. The pHLsec vector contains the extracellular domains of
HLA -DR4 (DRA*01:01/DRB1*0401) α and β chains and C-terminal enterokinase cleavable
fos/jun zippers to promote dimerization. The β chain contains a BirA site for biotinylation and
tetramer generation and a Histidine tag for Immobilized Metal Affinity Chromatography (IMAC)
purification. An ampicillin resistance gene is included in both DRA DNA & pHLsec DRB1*04:01
DNA plasmids. The maps below were designed using SnapGene Viewer, version 5.1.5, from GSL
Biotech; available at www.snapgene.com.
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A. pHLsec plasmid map
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B. pHLsec DRA map
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C. pHLsec DRB1 04 map
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Table 1 DNA Sequence of DRA and DRB1 04
Vector/DNA
Sequence

Sequence

pHLsec DRA

GAATTCAAGCTTGCCGCCACCATGGGAATCCTGCCTTCACCCG
GAATGCCTGCGCTTCTGTCACTGGTGTCGTTGCTTTCGGTACTC
CTGATGGGATGCGTGGCCATTAAGGAGGAACACGTCATCATTC
AGGCGGAGTTCTATCTGAACCCGGATCAATCGGGCGAGTTTAT
GTTCGACTTCGACGGTGATGAGATCTTCCATGTGGATATGGCA
AAGAAAGAGACAGTCTGGCGCCTTGAAGAATTTGGGAGGTTCG
CCAGCTTTGAGGCCCAAGGTGCCCTCGCGAATATCGCTGTAGA
CAAAGCGAACCTTGAAATCATGACGAAGAGATCTAACTATACT
CCGATTACGAACGTGCCACCGGAGGTCACGGTGCTCACCAACT
CCCCGGTGGAGCTGAGGGAGCCAAATGTGTTGATCTGTTTCAT
CGATAAGTTTACCCCTCCCGTCGTCAACGTAACATGGTTGCGA
AATGGTAAACCGGTGACAACAGGCGTTAGCGAAACTGTATTCC
TTCCACGTGAGGATCACCTCTTTCGGAAATTCCATTACCTCCCT
TTTCTGCCCTCCACGGAGGACGTGTACGACTGTCGAGTTGAAC
ACTGGGGACTTGACGAACCCTTGTTGAAGCATTGGGAGTTTGA
TACTAGTGGGGACGATGATGATAAGGGAAGTGGGAGCGGGCT
CACAGACACCCTCCAAGCCGAAACGGACCAGCTGGAAGATGA
AAAGTCAGCACTTCAGACGGAGATTGCGAATCTGTTGAAAGAA
AAAGAAAAACTTGAGTTTATCCTTGCAGCGTAATGATCACTCG
AG

PHLsecDRB1 04

GAATTCAAGCTTGCCGCCACCATGGGGATTCTGCCTTCACCTGG
GATGCCTGCTCTGCTGTCTCTGGTCTCTCTGCTGTCAGTCCTGCT
GATGGGATGCGTCGCTTGGAGCCACCCACAGTTCGAGAAGGGA
GCACCTGTGTCCAAAATGAGAATGGCTACACCACTGCTGATGC
AGGCAAGCGGGGGAAGCGGAAGTATTGAGGGGCGGGGATCCG
GGGACACCCGACCACGTTTCTTGGAGCAGGTTAAACATGAGTG
TCATTTCTTCAACGGGACGGAGCGGGTGCGGTTCCTGGACAGA
TACTTCTATCACCAAGAGGAGTACGTGCGCTTCGACAGCGACG
TGGGGGAGTACCGGGCGGTGACGGAGCTGGGGCGGCCTGATG
CCGAGTACTGGAACAGCCAGAAGGACCTCCTGGAGCAGAAGC
GGGCCGCGGTGGACACCTACTGCAGACACAACTACGGGGTTGG
TGAGAGCTTCACAGTGCAGCGGCGAGTCTATCCTGAGGTGACT
GTGTATCCTGCAAAGACCCAGCCCCTGCAGCACCACAACCTCC
TGGTCTGCTCTGTGAATGGTTTCTATCCAGGCAGCATTGAAGTC
AGGTGGTTCCGGAACGGCCAGGAAGAGAAGACTGGGGTGGTG
TCCACAGGCCTGATCCAGAATGGAGACTGGACCTTCCAGACCC
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TGGTGATGCTGGAAACAGTTCCTCGGAGTGGAGAGGTTTACAC
CTGCCAAGTGGAGCACCCAAGCCTGACGAGCCCTCTCACAGTG
GAATGGAGAGCAACCGGTGGCGACGATGATGACAAGGGTTCA
GGGTCTGGGAGAATTGCCCGACTCGAAGAGAAAGTCAAAACG
TTGAAAGCGCAAAACTCGGAGCTGGCTTCAACCGCGAATATGC
TCCGTGAACAGGTCGCGCAGTTGAAACAGAAGGTGGGAAGCG
GTTCGGGAGGGTTGAATGACATTTTCGAAGCGCAGAAGATCGA
GTGGCACGAGGGCTCAGGCCATCATCATCACCATCACCACTAA
TGATCACTCGAG

Table 2 Protein sequence of DRA and DRB1.04
Vector/Protein
sequence

Sequence

pHLsec DRA

MGILPSPGMPALLSLVSLLSVLLMGCVAIKEEHVIIQAEFYLNPDQ
SGEFMFDFDGDEIFHVDMAKKETVWRLEEFGRFASFEAQGALANI
AVDKANLEIMTKRSNYTPITNVPPEVTVLTNSPVELREPNVLICFID
KFTPPVVNVTWLRNGKPVTTGVSETVFLPREDHLFRKFHYLPFLPS
TEDVYDCRVEHWGLDEPLLKHWEFDTSGDDDDKGSGSGLTDTL
QAETDQLEDEKSALQTEIANLLKEKEKLEFILAA--

PHLsecDRB1.04

MGILPSPGMPALLSLVSLLSVLLMGCVAWSHPQFEKGAPVSKMR
MATPLLMQASGGSGSIEGRGSGDTRPRFLEQVKHECHFFNGTERV
RFLDRYFYHQEEYVRFDSDVGEYRAVTELGRPDAEYWNSQKDLL
EQKRAAVDTYCRHNYGVGESFTVQRRVYPEVTVYPAKTQPLQHH
NLLVCSVNGFYPGSIEVRWFRNGQEEKTGVVSTGLIQNGDWTFQT
LVMLETVPRSGEVYTCQVEHPSLTSPLTVEWRATGGDDDDKGSG
SGRIARLEEKVKTLKAQNSELASTANMLREQVAQLKQKVGSGSG
GLNDIFEAQKIEWHEGSGHHHHHHH
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Transformation into competent E. coli

The plasmids containing DRB1*04 and DRA*0101 genes were separately transformed into NEBSTBL (NEB; Cat#C3040H) competent cells. 2ul of each plasmid (see supplementary) was added
to 25 µL of the competent cells and incubated at 4 °C for 30 minutes, then they were heat shocked
at 42°C for 42 seconds and returned to ice 4°C for 2 minutes. The transformation mix was diluted
into 1 ml of SOC and incubated at 37°C with shaking at 250 rpm for 1 hour. After incubation, the
10uL or 100 µL of transformation was each plated onto 10 cm LB agar plates containing ampicillin
antibiotic (see supplementary) and incubated at 37°C overnight.

After 24 hours, colonies of E. coli containing the plasmid of interest was grown in 3mL of LB
media plus 50 ug/ml of ampicillin antibiotic overnight. The plasmid DNA was extracted using
DNA miniprep kit (Biobasic; Cat#BS88503. The plasmid DNA were digested with EcoRI
restriction enzyme to check the purity of the preparation and the correct size of each plasmid. One
of the plasmids preps, presenting the corrected size and the cleanest band was transformed again
to do a maxiprep using the maxiprep kit (Biobasic; Cat#9K0060023). After maxi prepping, the
products underwent restriction digestion using EcoRⅠ restriction enzyme to again check for the
size and purity of the preparation.

Figure 9 Transformation of E. coli

31

Digestion of Plasmids

Restriction digestion of the plasmids was performed in 10 µl of solution containing: 5 µl of plasmid
DNA, 1 µl of EcoRⅠ, 1 µl of fast digest green buffer and 3µl H2O for miniprep extraction and 10
µl of solution containing: 2 µl of plasmid DNA, 1 µl of EcoRⅠ, 1 µl of Fast Digest green buffer
and 6µl H2O for maxiprep extraction. Reactions were incubated at 37°C for 30 minutes and
analysed by agarose gel.

Agarose DNA gels:

Agarose gels were made up to 1% (w/v) Agarose in 1X TAE containing 1 µl ethidium bromide.
After solidifying the gels, prepared samples were loaded into the wells. Gels were run in a tank
containing 1X TAE for 30 min at 100 V. Bands were visualised by UV using Alpha Innotech gel
imaging system.

Antibodies
The following antibodies were used in western blotting and immunofluorescence analysis:
Anti His rabbit (Santa Cruz Biotechnology – Cat # sc-803)
Anti HLA-DR human Clone L243 (Thermofisher, Cat #5011313)
Alexa 488 rabbit (Thermo - Life Technologies Cat # A11008)
α-rabbit IgG peroxidase conjugated (Sigma Cat # A0545)

Mammalian Cell Culture
HEK-293 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with
10% Fetal Bovine Serum (FBS; Thermo-Fisher; Lot#906532) and 1% Penicillin-Streptomycin
(Gibco; Cat#1514122) at 37°C in 5% CO2 overnight (see the supplementary).
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Protein expression & concentration determination

Cells at the confluency of 70% were transfected with 10 µg of DNA and 30 µg branched
polyethyleneimine reagent (PEI, Sigma; Cat# 408719). After 24 hours the media was changed with
the fresh growth media and the transfected cells were incubated for 48 hours at 37 °C in 5%. CO 2.
The transfected cells were collected by pipetting and spinning at 1000 rpm for 5 min at 4°C,
washed once with 1X PBS, and were used for cell lysis. Cells were lysed with TNE (50mM Tris
pH 8.0, 150 mM NaCl, 0.5 mM EDTA, 1% Triton). Bradford assay were used to determine the
protein concentrations. Briefly, 995 µL of Bradford reagent was quickly added to 5µL of lysate.
The standard curve was made just before the measurement of the sample using Bovine Serum
Albumin and needed regression of 0.960 or higher before proceeding.

Western Blotting

SDS-PAGE or non denature PAGE (see supplementary section for recipe) was used to evaluate
the presence of recombinant proteins (DRα, DRβ) separately and both chains together (DRαβ),
respectively. In SDS-PAGE, western blotting the samples were denatured and run on a 10%
sodium dodecyl sulfate poly acrylamide gel at 120 V for 2 hours. Then the proteins were
transferred onto a 0.45 um polyvinylidene fluoride (PVDF) membrane (Millipore Cat#
IPVH00010) at 30 V for 2 hours. After the transfer, the membrane was blocked with 1% milk in
Tris-buffered saline with 10% Tween-20 (TBST) for 1 hour at room temperature while it is on the
rotator. Following of the blocking the membrane, membrane was incubated with primary antibody
(1:1000) anti his tag at 4°C overnight on the rotator. The next day, the membranes were washed 3
times with TBST for 10 minutes and then was incubated 1 hour with the second antibody anti
rabbit (Santa Cruz Biotechnology Cat # sc-803) (1:10000) at 4°C on the rotator. Afterwards the
membrane was washed with TBST for 5 minutes. To make the membrane ready for the
chemiluminescence imaging, a solution of (1:1) ECL (enhanced chemiluminescent substrate) and
0.01% H2O2 reagents (Thermo-Fisher; Cat#32106) were used right before the imaging by Alpha
Innotech equipment.
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Immobilized Metal affinity chromatography
Poly-histidine tagged (HLA-DRαβ) protein was purified using Immobilized metal affinity
chromatography. 2 ml Thermo Pierce Centrifuge columns were packed with IMAC Sepharose 6
Fast Flow (GE Healthcare) and were washed with 5 column volumes of distilled water to remove
the 20% ethanol. Afterwards, the resin was charged with 0.1 M solution of Ni 2+ ion. Then the
columns were washed with at least 2 column volumes of distilled water to remove the excess metal
ions. The columns were equilibrating with 5 column volumes of binding buffer (20 mM sodium
phosphate, 0.5 M NaCl, 20 to 40 mM imidazole, pH 7.4 which was followed by applying the
protein lysate. Then the columns were washed with binding buffer followed by using 5 column
volumes of the elution buffer (20 mM sodium phosphate, 0.5 M NaCl, 500 mM imidazole, pH
7.4.). After elution, the columns were regenerate the columns by washing them 5 to 10 column
volume of binding buffer and the samples were kept in -80 ºC freezer for the next experiments.

Flow Cytometry

HEK-293 cells were cultured and transfected as described previously. 1 x 106 cells were
resuspended in staining buffer (BD 554656) and incubated with Anti Hu HLA-DR (L243 PE) or
anti HIS plus Alexa 488 antibodies for 1 hour in 4°C. After staining the cells were washed three
times with 1X PBS (see supplementary for the recipe) and analyzed using using BD Fortessa X20
cytometer using the 488 nm filter for His Tag-Alexa 488 and 561 nm filter for L243-PE dyes
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Results
The plasmids containing DRB1*0401 and DRA*0101 genes were extracted using a mini prepping
kit and maxi prepping kit. (A). Vector maps of the DRB1*0401 and DRA*0101. (B) Agarose DNA
gels of successful mini prep extraction of DRB1*0401 and DRA*0101 DNA. (C) Agarose DNA
gels of successful maxi prep extraction of DRB1*0401 and DRA*0101 DNA (D) The
concentration and purity of DRB1*0401 and DRA*0101 DNA., control vector (pHLsec) was used
as a control.in all the experiments.
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D
C: ng/ul

purity

pHLsec

424.2

1.88

DRB*0401

655.4

1.88

DRA

654

1.88

Figure 10 The vectors consist of extracellular domain of the DRB1*0401 and
DRA*0101 cloned into PHLsec were used for high yield DNA extraction.
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The DRB1*0401 and DRA*0101 Extra Cellular Domain were used to transfect HEK293 cells
when the cells reached the concentration of 6 ×106 cells/mL. (A) The concentration of the protein
in the lysis and, (B) successful western blot using anti his antibody results shows that the chains
were expressed.

A

Concentration ug/ml of protein lysed from HEK
293 cells transfection

2.6
2.55
2.5
2.45
2.4
2.35
2.3
2.25
2.2
2.15

DRα

DRβ

DRαβ

C

B

Figure 11 Expression of DRB*0401, DRA 0101, a combination of both chains in
HEK293 mammalian cells and a control without transfection
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FACS analysis of cell-surface expression of DRA molecules after transfection with vector for
DRA, DRB, or the combination of both. L243 stain (top panel) and His tag stain (bottom panel)
illustrate that both chains are assembled and located in the cell surface

L243 stain
Black DRA
Blue DRB
Red both

His tag stains
Black – DRA
Blue DRB
Red both

Figure 12 Detection of the HLA complex by Flow Cytometry using (A)L243 stain and
(B) His tag stain illustrates that both chains are assembled.
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A

B

Figure 13 Purification of the HLA complex by IMAC.
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Discussion

Biopharmaceutical companies produce many drugs to target proteins from specific pathways in
autoimmune diseases and cancers. Proteins are expressed, or produced, by transcribing DNA to
messenger RNA (mRNA); the translation of this mRNA into polypeptides is followed by their
folding into the functional protein. Advent of recombinant protein become important for structural
and biophysical studies, functional assays, drug development and for therapeutic applications in
biopharmaceutivals63. Protein folding does certainly occur spontaneously as the protein is
prepared; however, it often requires the intervention of chaperone proteins, complex aggregates of
proteins (such as HLA class Ⅰ noted in the introduction, or the need for MHC class Ⅱ to have
peptides present to maintain their structure), and often post-translational modifications such as
glycosylation or phosphorylation that require other enzymes. The primary structure does not
provide the post-translation information, and often the crystal data we have on these proteins
involve stripping away glycosides or other post-translational modifications that are necessary for
function. This is mainly a feature of the difficulty of interpreting these types of proteins, but it
often needs to be reiterated: X-ray crystal structures are often simply modelling of the protein,
stripped of some of its essential components, and frozen in a single conformation that may or may
not be related to the biologically active conformation or species. It’s important to take into account
the post-translation modifications in each protein to better understand its structure for drug
development.

Consequently, the choice of host species for the expression and purification of the desired protein
plays an important role for the characterization of proteins and ligands interactions. MHC is
studied in a several autoimmune disease s and cancers64. The first step to produce a MHC
recombinant protein is getting its gene cloned and the protein amplified in the chosen expression
system. As discussed in the introduction HLA DR4 is implicated in 65% of rheumatoid arthritis
cases and is the genetic locus most highly associated with disease development. This protein
complex consists of both an α and a β chain. The DNA sequence of the α chain is almost completely
conserved in each class and between individuals. It is exclusively coded by DRA*0101 allele.
However, the β chain is extremely polymorphic, coded by over 1700 different alleles. The allele
DR4 is the most common one in rheumatoid arthritis patients and has excellent well-known affinity
for the dominant immunogenic peptide sequence from type II collagen. For the studies in this
thesis, we expressed and purified HLA-DR4 is our first peptide model to evaluate the peptidedrugs interaction

Success in expressing foreign genes in heterologous living organisms to produce the target proteins
is sensitive to many different parameters such as choice of host, choice of plasmid and choice of
purification tag65For our project, an appropriate protein expression system is the maximum
importance to express this heterodimeric glycosylated protein HLA -DR4

40

(DRA*01:01/DRB1*0401). Determining which of these should be used was the first step of this
thesis. There are broadly three ways to approach this problem. The first is to try the different
systems. This is lengthy and perhaps unnecessary. The second is to identify a consensus in the
literature of which approach should be used. This was impossible to find as there is no consensus.
The third, and the one we used, was to conduct an exhaustive comparative review of the approaches
outlined in the literature to compare and contrast the success of previous approaches. Upon starting
my MSc in September 2019, determining the best route forward was the focus of my masters thesis
for the first three months.

Various host systems have been previously used to express the HLA including mammalian cell
culture, baculovirus system, bacteria, and yeast. Each host system has positive and negative points,
with the balance towards being preferred depending on the purpose of the study. Choice of host is
a crucial step in expression of this protein which has a great impact on the yield, functionality, and
stability of the protein. The location of HLA complex, expressed as it is on the surface of antigen
presenting cells including macrophages, dendric cells and B cells, will affect the choice of method
of isolation and purification of the product. This choice was the critical first decision of the thesis.
When the project began, our lab was leaning towards a baculovirus-insect cell system; however,
we were aware that this was a partially arbitrary decision, and consequently the first task was to
determine the preferred system for HLA expression. There is no consensus in the literature, and
there is no body of literature comparing the relative merits of the different systems. One of the
expected deliverables of this thesis is a systematic critical review of HLA expression tools; the
article is currently being finalized and is expected to be submitted to HLA, the journal of record
for MHC-related immunology, following correspondence between Dr. Trant and the editorial
board. This publication is the result of my efforts to outline and contrast the various strategies.

Expression Conditions
Mammalian cell culture is one the most common methods to express recombinant human proteins.
This method has become the preferred system to express recombinant proteins due to the presence
of all the proper machinery required for proper protein folding and posttranslational glycosylation
which are carried out in the endoplasmic reticulum and Golgi apparatus of mammalian cells. HLA
is an α/β heterodimer glycosylated membrane protein; functional HLA molecules only can be
produced in mammalian cells66. So, it is crucial to use a proper host to express this protein to
include post translational modifications.

There are a couple of different mammalian cell lines which have been used to express proteins
including Chinese hamster ovary (CHO) cells, baby hamster kidney (BHK) cells, myeloma (NS0,
SP2/0), HeLa, Vero, murine 3t3 fibroblast cells and HEK293 cells67. CHO cells are used for
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approximately 60% of all expressions of the therapeutic proteins because they are able to produce
a productive and high titre yield and also lower biosafety risk however, they can not be a great
host choice to express proteins because of generating non-human glycan structures including in
N-glycolylneuraminic acid (Neu5Gc) and galactose-alpha-1,3-galactose group (α-Gal) onto
glycoprotein products which confers increased risk of immunogenicity.68 67 To produce more
human-like protein therapeutics , efforts have been made to produce human cell lines such as
HEK293 , HT-108067. In particular, the HEK293 cell line has become one of the most common
human cell lines to express the proteins due to easy manipulation and rapid production of
recombinant proteins, however, the total yield is one of the main challenges in using this specific
cell line69. As you see in table number 10 the cell lines used in different studies is listed. Nobuo
Watanabe and his colleagues have shown that using mammalian cell culture is the best method to
produce α/β heterodimeric glycosylated membrane proteins; this was confirmed by us in our
results. (Table 10). Moreover, the selection of HEK293 expression was so favorable to IMAC
purification as the harvest lysate can be loaded directly to Ni charged columns before buffer
exchange. Therefore. IMAC was chosen to purify the protein based on the acceptable yield and
purity (Figure 13)
Other methods such as Baculovirus mediated insect cells or yeast has been used to produce α/β
heterodimeric glycosylated membrane However, the baculovirus system has several limitations.
The lytic infection process leads to the release of host & viral proteases which affects the protein
quality. Some viral proteins such as v-cathepsin and v-chitinase stop the secretary pathway of the
protein resulting in repeated rounds of virus amplification and they also make defective particles
and reduce the yield. Some studies have shown that deleting these viral proteins can improve the
production of secreted proteins. Although, this method has been widely used to express human
leukocyte antigens, purification can be challenging. IMAC chromatography, exploiting the His tag
on our construct, is the preferred method for purification. However, IMAC chromatography is
rarely successful from baculovirus expression systems as the high molecular weight o-Pluronic
acid, standard in the baculovirus media, can strip to the column.

Past studies have used yeast for the expression of human genes, supporting use of HLA expression
in yeast. The most common yeast vectors for HLA expression have been Pichia pastoris and yeast
artificial chromosomes (YACs). Though no studies have explicitly stated their reasoning for using
YACs for HLA expression, it has been shown to be a successful and favoured vector for HLA
expression (table 12). However, YACs do have limitations. Protein expression has been shown to
vary and have inconsistencies between various YAC clones. The inconsistency may be due to
alternative splicing of exons of the HLA gene or the lack of tissue specificity in YACs expressing
a human gene. YACs are also prone to chimerism and lack of stability, which may contribute to
overall difficulty with reproducibility and high-volume HLA expression.
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There are not many reports providing head-to-head comparisons of these different vectors, so it is
not trivial to identify the best method to express and purify the HLA protein. As the research steps
forward for clinical trials more factors will be taken into consideration. Different studies in the
production of recombinant proteins have been shown that mammalian cells are the best method
among different expression systems to produce the protein because they can perform complex
post-translational modifications that are necessary for efficient secretion, drug efficacy, and
stability. These modifications consist of misfolding and aggregation, oxidation of methionine,
deamidation of asparagine and glutamine, variable glycosylation, and proteolysis. These
modifications are not only input so many challenges to produce an accurate protein, but also may
lead to incorrect results in the study of human leukocyte antigen. Unfortunately, the yields, titres,
and costs of this method are all unfavourable. Our results showed that the concentration of purified
protein 0.14 ug/ul from 1 ml of lysate is sufficient for use with our biophysical evaluation tools
we wish to employ in our drug-screening such as surface plasmon resonance and fluorescence
displacement assays. Thus, we chose to use this route, as proper folding is essential for our
purposes, using HLA was already a significant compromise, we could not accept further deviations
from the in vivo conformation of the protein.

Protein purification
IMAC has the advantage of purifying HLA with high affinity, specific binding and selectivity by
using imidazole in chromatography buffers. Native PAGE bands in our results are showing
specificity and purity of using IMAC to purify HLA. Moreover, Histidine tags between four to ten
residues provides the strongest affinity for the chromatography. Ni2+ is one the most common
metals used for his-tag purification which gives a high yield.

SDS-PAGE and Native PAGE analysis

After protein expression and purification, a sample was evaluated by SDS-PAGE analysis. The
blotting with anti Histag antibody confirmed that DRα, DRβ has been expressed using HEK293
cell line. However, SDS-PAGE was not able to confirm that the complex DRαβ has been formed.
SDS-PAGE gel is a denaturant system. In order to confirm that both chains are assembled and
expressed on the surface of membrane, Flow Cytometry using L243 stain (anti-HLA antibody
recognize DRαβ when they are conformationally assembled) and His tag stain illustrates that both
chains are assembled (fig 13B.) Our Native-PAGE using Coomassie blue dye with the intensity of
the bands showing DRαβ are assembled after purification

The main finding of our thesis are as follows. Human leukocyte antigen is a protein needed to
advance the research and drug development in autoimmune diseases and cancers. In these early
stages of this project, we showed that choice of HEK293 cell as a host to express HLA protein and
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IMAC chromatography as a purification system gives us a reasonable amount of α/β heterodimer
glycosylated membrane HLA protein.

Surface Plasmon Resonance
One of the commonly used technologies is Surface plasmon resonance (SPR) for detailed and
quantitative studies of protein-peptide interactions and determination of their equilibrium and
kinetic parameters. Tracking the change in the SPR signal over time generates a sensogram, a plot
of the binding response (RU) versus time which allows different stages of a binding event to be
visualized and evaluated. During the injection of an analyte, the binding response increase because
of the formation of analyte(peptide)–ligand(protein) complexes at the surface and the sensorgram
is dominated by the association phase. After a certain time of injection, a steady state is reached,
in which binding and dissociating molecules are in equilibrium. The decrease in response after
analyte injection is terminated because of dissociation of the complexes, defining the dissociation
phase. Depending on the dissociation rate of the tested ligand, some assays may require a
regeneration step in order to reach the baseline again. Fitting the sensorgram data to an appropriate
kinetic binding model allows calculation of kinetic parameters such as the association (ka) and
dissociation (kd) rate constants, and the binding affinity of the tested interactions. The SPR (surface
plasmon resonance) analysis is currently underway in our lab to confirm the binding of HLA*DR4
to human cartilage glycoprotein 39 as a control to evaluate the binding affinity of this self peptide
to the target protein. This whole research was conducted under COVID restriction at the University
of Windsor for over 16 month of the last two years and for personnel reasons restrict my time in
the lab since February 2021.
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Supplementary methods
Transformation
1. Place NEB-STBL (NEB; Cat#C3040H) competent cells vials into ice immediately from -80°C.
2. They should stay in the ice to get thawed for approximately 5 minutes.
3. Add 2µl of 701.62 µg/µl pHLsec DRA DNA, 892.67 ng/µl pHLsec DRB1*0401 DNA and
165.88 ng/µl empty pHLsec vector plasmids to 25 µL of the competent cells and incubated at
4 °C for 30 minutes.
4. Place them into the water bath at 42°C for 42 seconds for heat shock.
5. Return them immediately to ice 4°C for 2 minutes.
6. Dilute the transformation mix into 1 ml of SOC media and incubate them at 37°C with shaking
at 250 rpm for 1 hour.
7. Plate 10 µL or 100 µL of transformation each onto 10 cm LB agar plates containing ampicillin
antibiotic and incubate them at 37°C overnight.
8. After 24 hours, add a couple of colonies of E. coli containing the plasmid of interest to 3mL
of LB media plus 50 µg/ml of ampicillin antibiotic overnight.
9. Extract the plasmid DNA using DNA miniprep kit (Biobasic; Cat#BS88503) and the maxiprep
kit (Biobasic; Cat#9K0060023).
10. Mini prepping and Maxi prepping should be follow using the company instruction kit.

LB agar plates containing ampicillin antibiotic recipe
LB Agar Powder, Miller, (Biobasic, CAT. #: SD7003) is made following manufacture’s
protocol. It should be autoclaved. After it gets cool mix with 100 ug/ml Ampicillin antibiotic.

Fast Digest Restriction enzyme
The 10X Fast Digest Green Buffer includes a density reagent and two tracking dyes for direct
loading. The blue dye migrates with 3–5 kb DNA fragments in a 1% agarose gel and has an
excitation peak of 424 nm. The yellow dye migrates faster than 10 bp DNA fragments in a 1%
agarose gel and has an excitation peak of 615 nm.
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Thaw and split HEK293 cell (Human embryonal kidney cells: (HEK293, ATCC [Cat. No. CRC1573])

Growth media: Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% Fetal
Bovine Serum (FBS; Thermo-Fisher; Lot#906532) and 1% Penicillin-Streptomycin (Gibco;
Cat#1514122).

Thaw

Preparatory Work: Warm media to 37°C in water bath

1. Frozen cells completely should get thaw in hands.
2. Transfer the cells to 15 ml tube and spin at 1000 rpm for 5 min.
3. Remove the Supernatant and resuspend the pellet with 1 ml of media and transfer the cell
suspension to 10 cm plate containing 7 ml of media.
4. Incubate the Cells at 37°C and 5% CO2.

Seeding the Cells

Preparatory Work: Warm media and PBS to 37°C in water bath
PBS1X (make and keep it as a stock)

1. Check the Cells on plate by microscope to see if they are healthy and see confluency of cells
(usually good to have about 70-80% coverage of plate.
2. Remove the media and wash the cells with 1ml PBS and place them into a 15ml test tube and
spin them in the centrifuge at 1000RPM for 5 minutes.
3. Discard the supernatant and add fresh room-temperature growth media to the pellet (amount
of media depends on size of pellet, but usually 4-5mls) and resuspend pellet.
4. Add 50 µl Trypan Blue into Eppendorf tube to 50 µl of the media and cells and count cells
using hemocytometer.
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5. Place 10 µl in hemocytometer and counted the four quadrants. Average of cells from the four
quadrants and times by 2x104. (Since 1:1 ratio solution and want ml. This gave us cells/ml).
To figure out how much resuspended media to add on new/seeding plates to get certain number
of cells (ml).
6. The calculated number of resuspended cells placed into media around the plate, cells and
spread around so they have room to grow.
7. The doubling time for HEK293 cells is 24 hours.
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SDS PAGE analysis

Prepare Gel Electrophoresis:

1. Make 10 % running gel (Table 3) and stacking gel (Table 4).

Table 3 Running Gel Recipe
Running Gel %

10%

H2O

15.5mL

Acrylamide

7mL

Running/Lower Gel Buffer

7.5mL

10% APS

112.5uL

TEMED (add last)

33.75uL

Table 4 Stacking Gel Recipe
Stacking Gel
H2 O

6.4mL

Acrylamide

1.125mL

Upper Gel Buffer

2.5mL

10% APS

30uL

TEMED (add last)

20uL

Preparing Protein Samples:
1. Pipette 80 ug of each protein (DRα, DRβ and DRαβ) lysate into an empty Eppendorf tube
2. Add TNE and sample buffer to each tube so that the max volume is ¼ sample buffer
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3.
4.
5.
6.

place the samples on a 95°C heat block for 5 minutes.
Spin down the samples and add the samples to the well.
Run the sample at 120 V for 2 hours in the gel electrophoresis buffer (Table 5).
Transfer the proteins onto a 0.45 um polyvinylidene fluoride (PVDF) membrane (Millipore
Cat# IPVH00010) at 30 V for 2 hours in transfer buffer (Table 6).
7. Block the membrane with 1% milk in Tris-buffered saline with 10% Tween-20 (TBST) for 1
hour at room temperature while it is on the rotator.
8. Then incubate the membrane with primary antibody (1:1000) anti his tag at 4°C overnight on
the rotator.
9. The next day, wash the membranes 3 times with TBST for 10 minutes and then incubate 1 hour
with the second antibody anti rabbit (Santa Cruz Biotechnology Cat # sc-803) (1:10000) at 4°C
on the rotator.
10. Afterwards wash the membrane with TBST for 5 minutes.
11. To make the membrane ready for the chemiluminescence imaging, use a solution of (1:1) ECL
(enhanced chemiluminescent substrate) and 0.01% H 2O2 reagents (Thermo-Fisher;
Cat#32106) right before the imaging by Alpha Innotech equipment.

Table 5 Running Buffer Recipe
1x Running Buffer Recipe (1L)
Tris Base

3.02g

Glycine:

18.8g

10% SDS

10mL

H2O

Fill container with water until solution
reaches 1L

Table 6 Transfer Buffer Recipe
1x Transfer Buffer Recipe (1L)
Tris Base:

5.8g

Glycine:

2.93g

10% SDS

10mL

Methanol (MeOH)

200mL

H2O

Add last, fill container with water until
solution reaches 1L
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Non denature PAGE

Table 7 Running Gel Recipe for Non-denatured PAGE
Running Gel %:

10%

H2O

15.5mL

Acrylamide

7mL

Running/Lower Gel
Buffer (1.5 M TrisHCl, pH 8.8)

7.5mL

10% APS

112.5uL

TEMED (add last)

33.75uL

Table 8 Stacking Gel Recipe for Non-denatured PAGE
Stacking Gel Recipe
H2O

6.4mL

Acrylamide

1.125mL

Upper Gel Buffer (0.5 M TrisHCl, pH 6.8)
10% APS

2.5mL

TEMED (add last)

20uL

30uL

Table 9 Gel Electrophoresis Running Buffer Recipe for Non-denatured PAGE
1x Running Buffer
Recipe (1L)
Tris Base:

3.g

Glycine:

14.4g

H2O

Fill container with water until
solution reaches 1L pH 8.3
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Samples should be diluted accordingly with 5X sample buffer: 0.1M Tris-HCl (pH 6.8), 30%
glycerol, 80 µg/ml bromophenol blue to give a solution that is 1X sample buffer and run on a
10% native poly acrylamide gel at 120 V for 3 hours After 3 hours the gels were stained in
protein stain consist of 0.25 g Coomassie brilliant blue, 125 mL methanol, 25 mL glacial acetic
acid, and 100 mL water. After staining overnight, the gels were washed with distaining solution
(100 mL methanol, 100 mL glacial acetic acid, and 800 mL water) for 1 hour.
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Table 10 Studies used mammalian cell culture to express human leukocyte antigen
HLA Allele Cell Line
A2
B27

DRA

DRB

Author(s)

Human lymphoblastoid cell line JY

Bjorkman70

Human B lymphoblastoid cell line LG-2

Gorga71

CHO

Serra72

HeLa

Lotteau73,
Salamero74

Dap.3 subclone of class II-negative murine L
fibroblast

PaninaBordignon75

NIH 3T3

Korman76

Rat2

Hitzel77

Human B lymphoblastoid cell line LG-2

Gorga78

L929

Höpner79

CHO

Serra72

HeLa

Lotteau73,
Salamero74

Dap.3 subclone of class II-negative murine L
fibroblast

PaninaBordignon75

NIH 3T3

Korman76

L929

Höpner79

Human B lymphoblastoid cell line LG-2

Gorga78, Valli80

TR81.19 fibroblast

Sette81

L257.6 fibroblast

Sette81

L466.1 fibroblast

Valli80,
Wucherpfennig82

L416.3 fibroblast

Valli80,
Wucherpfennig82

L242.5 fibroblast

Valli80

L255.1 fibroblast

Valli80

52

DR1

MAT

Valli80

Priess

Valli80

BIN40

Valli80

SWEIG

Valli80

Pitout

Valli80

Human B lymphoblastoid cell line LG-2

Gorga83

Dap.3 subclone of class II-negative murine L
fibroblast

Klohe84,
Koehler85

LG-2

O’Sullivan86–88,
Sette81,89

HeLa

van Lith90

MST

Gorga83

GMO 3107 lymphoblastoid cell line

Nag91

3107 EBV cells

O’Sullivan86–88

L416.3 fibroblast

Sette81

WT20

Gorga83

Rat2

Hitzel77

GMO 8067 lymphoblastoid cell line

Nag91

MAT

O’Sullivan86,88,
Sette81

Murine fibroblast

Boen92, Klohe84

Priess

Gorga83, Sette81,89

GMO 6821A lymphoblastoid cell line

Nag91

BIN40

Sette81,89

Dap.3 subclone of class II-negative murine L
fibroblast

Klohe84

SWEIG

O’Sullivan86–88,
Sette81

Mann

Gorga83

Dap.3 subclone of class II-negative murine L
fibroblast

Klohe84

DR2

DR3

DR4

DR5

DR7
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DR8

DRB

DO

DQ

DP

Pitout

Sette81,89

23.1

Gorga83

CHO

Day93

Human lymphoblastoid cell lines BSM, 2046,
and MT

Hammer94

Priess

Liu95

HeLa

Brunet96

Human B lymphoblastoid cell line LG-2

Gorga78

Dap.3 subclone of class II-negative murine L
fibroblast

Klohe84

HeLa

van Lith90

Human B lymphoblastoid cell line LG-2

Gorga78

Dap.3 subclone of class II-negative murine L
fibroblast

Klohe84

HeLa

van Lith90

Table 11 Studies used baculovirus system to express Human leukocyte antigen
HLA Allele

Cell Line

Author(s)

A1

Sf9 insect

Smith97

Sf9 insect

Smith97

High Five insect

Mancino98

B27

Sf9 insect

Lévy99

B35

High Five insect

Thammavongsa100

Sf9 insect

Chou101, Narayan102,
Natarajan103, Sadegh-Nasseri104,
Stern105

A2

DR1
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DR2
DR4
DQ2

High Five insect

Smith97

Sf9 insect

Gauthier106

Sf9 insect

Fourneau107, Scheirle108

Sf9 insect

Jüse109, Kim110, Quarsten111

High Five insect

Xia112
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Table 12 YAC clones used for HLA expression and their respective HLA gene
incorporation, insert size and reference.
HLA fragment

YAC
Clone

Author

HLA-DRA

A95C5

Kozono et al.113

From HLA-DQB2 locus through DRA
locus

B1D12

Chen114.; Kozono113

Centromeric of HLA-DOB to interval
between HLA-DQA1 and HLA-DRB1

A148A7

Demmer and
Chaplin115; Kozono 113

HLA-B and -C

B38D3

Bronson 116

HLA-B and -1.7p

B92H5

Bronson

HLA-C

B209D7

Bronson

HLA-DMA, -DMB, -DOB, -DQA2, DQB2,
-DQB3, -DQB1 and -DRB1

11.2

Ragoussis, Trowsdale,
and Markie117

HLA-DOB, -DQA2, -DQB2, -DQB3, DQA1, -DQB1, -DRB1, -DRB2, DRB3, and -DRA

4D1

Ragoussis, Trowsdale,
and Markie 117

HLA-E and -A

225B1

Wei et al. 118

HLA-B and -C

152G3

Wei et al.

HLA-E

A231G12

Wei et al.

HLA-G and -F

A190C8

Wei et al.

HLA-A

B30H3

Wei et al.

HLA-DQB1 to -DRA

4D1D11

Fabb et al. 119

LMP2-DRA

4D1D10

Fabb et al.

DQB3-DRB1

11.2C10

Fabb et al.

LMP2-DRB1

11.2A1

Fabb et al.

HLA-DQw2
(DQA*0501/DQB1*00201) and -DR3
(DRA*0101/DRB1*0301/DRB3*52)

4D1

Chen et al. 120

HLA-DR4 to -DQ3

748D9

Chen et al.
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